You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CNS, CAR T cell, HER2-positive, brain tumor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Brain Tumor, Recurrent, Brain Tumor, Refractory Trial in Houston (HER2-specific T cells)

Recruiting
  • Brain Tumor, Recurrent
  • Brain Tumor, Refractory
  • HER2-specific T cells
  • Houston, Texas
  • +1 more
May 3, 2022

CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (HER2-specific chimeric antigen receptor (CAR) T cell)

Recruiting
  • Central Nervous System Tumor, Pediatric
  • +8 more
  • HER2-specific chimeric antigen receptor (CAR) T cell
  • Seattle, Washington
    Seattle Children's Hospital
Dec 14, 2022

Malignant Tumor, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the Leptomeninges Trial in Duarte

Recruiting
  • Malignant Neoplasm
  • +4 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • Duarte, California
    City of Hope Medical Center
Sep 14, 2022

Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult Trial in Seattle (SC-CAR4BRAIN)

Not yet recruiting
  • Diffuse Intrinsic Pontine Glioma
  • +4 more
  • SC-CAR4BRAIN
  • Seattle, Washington
    Seattle Children's Hospital
Mar 3, 2023

CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)

Active, not recruiting
  • Central Nervous System Tumor, Pediatric
  • +8 more
  • EGFR806-specific chimeric antigen receptor (CAR) T cell
  • Seattle, Washington
    Seattle Children's Hospital
Jan 18, 2023

HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)

Not yet recruiting
  • HER2 Positive Advanced Solid Tumors
  • HypoSti.CAR-HER2 T cells
  • +2 more
  • (no location specified)
Jan 12, 2023

Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

Not yet recruiting
  • Solid Tumor
  • Intravenous infusion anti-HER2-CAR-T cell
  • Shenyang, Liaoning, China
    Phase I Clinical Trials Center Of The First Hospital of China Me
Oct 30, 2023

HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer Trial in United States (chimeric antigen

Recruiting
  • HER-2 Gene Amplification
  • +4 more
  • chimeric antigen receptor (CAR) T cell therapy
  • Duarte, California
  • +6 more
Aug 10, 2022

Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Solid Tumor, Adult
  • CD70-targeting CAR-T cells
  • Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 8, 2023

Breast Cancer, Brain Metastases, Radiotherapy Trial in Shanghai (Combination use of SRT with T-DXd)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Combination use of SRT with T-DXd
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 14, 2023

Solid Tumor Trial (UCLM802 Cell Injection)

Not yet recruiting
  • Solid Tumor
  • UCLM802 Cell Injection
  • (no location specified)
Mar 7, 2023

Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland Trial in Houston (CAdVEC)

Recruiting
  • Bladder Cancer
  • +9 more
  • CAdVEC
  • Houston, Texas
    Baylor St. Luke's Medical Center
Feb 17, 2022

Glioblastoma Multiforme of Brain Trial in Duarte (CHM-1101 CAR-T cells)

Not yet recruiting
  • Glioblastoma Multiforme of Brain
  • CHM-1101 CAR-T cells
  • Duarte, California
    City of Hope Medical Center
Dec 19, 2022

T-Dxd in Treatment of HER2-positive BCBM After Prior Pyrotinib

Recruiting
  • Breast Cancer
  • Beijing, Beijing, China
  • +1 more
Nov 13, 2023

Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Not yet recruiting
  • Advanced Solid Tumor
  • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 9, 2023

Solid Tumor Trial in Shenzhen (bi-4SCAR GD2/PSMA T cells)

Recruiting
  • Solid Tumor
  • bi-4SCAR GD2/PSMA T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Solid Tumor Trial (HER2-E-CART cells)

Not yet recruiting
  • Solid Tumor
  • HER2-E-CART cells
  • (no location specified)
Feb 16, 2023

HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab)

Recruiting
  • HER2-positive Breast Cancer
  • Dendritic Cell (DC1) Vaccine
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
Dec 28, 2022

Ependymoma Trial in New York (HER2 Specific CAR T Cell)

Recruiting
  • Ependymoma
  • HER2 Specific CAR T Cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Apr 6, 2022

Metastatic Solid Tumor, Brain Metastases Trial in Houston (Trastuzumab emtansine, Tucatinib)

Not yet recruiting
  • Metastatic Solid Tumor
  • Brain Metastases
  • Houston, Texas
    M D Anderson Cancer Center
Dec 30, 2022

Digestive Tumor Trial (TM4SF1-positive chimeric antigen receptor T-cell therapy)

Not yet recruiting
  • Digestive Tumor
  • TM4SF1-positive chimeric antigen receptor T-cell therapy
  • (no location specified)
Dec 21, 2022

Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)

Not yet recruiting
  • Neuroendocrine Tumor (NET)
  • Colorectal Cancer (CRC)
  • CHM-2101 CAR-T cells
  • (no location specified)
Sep 20, 2023

Sarcoma Trial in Houston (Autologous HER2-specific T cells, Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Sarcoma
  • Autologous HER2-specific T cells
  • +3 more
  • Houston, Texas
  • +1 more
Nov 21, 2022

Solid Tumor Trial in Shanghai (aPD1-MSLN-CAR T cells)

Recruiting
  • Solid Tumor
  • αPD1-MSLN-CAR T cells
  • Shanghai, Shanghai, China
    Shanghai Mengchao Cancer Hospital
Oct 24, 2022

Breast Cancer, Brain Metastases, HER2-positive Breast Cancer Trial in Los Angeles (Tucatinib, Pembrolizumab, Trastuzumab)

Withdrawn
  • Breast Cancer
  • +3 more
  • Los Angeles, California
    Cedars-Sinai Medical Center
Jun 28, 2022